Ireland
--:--IST
Starting soon Not applicable

A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.

NCT07946666 · tracked via the Priya Life Science USA tracker
Sponsor
Epetome
Phase
Not applicable
Started
2026-11
Last updated
2026-11-18

Condition(s) studied

Gastrointestinal DiscomfortNauseaBloatingConstipationDiarrheaGLP-1 Receptor Agonist Therapy-Associated Gastrointestinal SymptomsObesityType 2 Diabetes

Investigational drug(s) / intervention(s)

Synbiotic Dual Cap® Intervention

Synbiotic Dual Cap® Intervention: Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.

Study summary

This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.

Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18-65 years. * Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment. * Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening. * Currently on a stable GLP-1 dose as directed by their prescribing physician. * Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12. * Willing and able to provide informed consent prior to enrollment. * In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant). * Reside in the United States. Exclusion Criteria: * Currently pregnant or breastfeeding (or planning to become pregnant during the study period). * Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period. * Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints. * Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period. * Anyone currently participating or planning to participate in another research study during the study period. * Currently receiving immunosuppressant therapy of any kind. * Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months. * Reside in Hawaii. * Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.

Primary outcome measure(s)

  • Change in Overall Gastrointestinal Comfort — Baseline to Week 12
    Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires
  • Change in Bowel Regularity — Baseline to Week 12
    Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires
  • Change in Bloating — Baseline to Week 12
    Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires
  • Change in Constipation — Baseline to Week 12
    Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires
  • Change in Diarrhea — Baseline to Week 12
    Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires
  • Change in Nausea — Baseline to Week 12
    Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires
  • Change in Post-Meal Fullness Comfort — Baseline to Week 12
    Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires

Trial sites (1)

FacilityCityRegionStatus
Citruslabs Las Vegas Nevada
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07946666 on ClinicalTrials.gov ↗ ← All trials in the USA